PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Gross profit growth similar to GNPX's 100.00%. Walter Schloss would assume both firms track common industry trends.
-1.47%
Negative EBIT growth while GNPX is at 33.67%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1.47%
Negative operating income growth while GNPX is at 33.67%. Joel Greenblatt would press for urgent turnaround measures.
-1.89%
Negative net income growth while GNPX stands at 33.56%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
2.63%
EPS growth under 50% of GNPX's 59.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.63%
Diluted EPS growth under 50% of GNPX's 59.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
3.22%
Share reduction more than 1.5x GNPX's 61.88%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.22%
Diluted share reduction more than 1.5x GNPX's 61.88%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative OCF growth while GNPX is at 62.28%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-50.21%
Negative FCF growth while GNPX is at 62.47%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while GNPX stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.36%
10Y OCF/share CAGR 1.25-1.5x GNPX's 77.93%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
62.52%
5Y OCF/share CAGR at 50-75% of GNPX's 87.60%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-48.56%
Negative 3Y OCF/share CAGR while GNPX stands at 71.79%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
94.18%
Similar net income/share CAGR to GNPX's 90.92%. Walter Schloss would see parallel tailwinds or expansions for both firms.
69.28%
5Y net income/share CAGR at 75-90% of GNPX's 79.50%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
-24.85%
Negative 3Y CAGR while GNPX is 57.31%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-50.75%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-32.62%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-67.01%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-15.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.46%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.75%
R&D dropping or stable vs. GNPX's 65.38%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-21.32%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.